Blog
Expedia Rises in Pre-Market Trading Despite First-Quarter Misses
Investors seem bullish about the prospects of online travel agency Expedia Group (NASDAQ: EXPE), even after the company posted first-quarter fiscal 2020 earnings that fell short of expectations.
The
Better Buy: Costco vs. Constellation Brands
The coronavirus pandemic has thrown many companies into unknown territory. But businesses can adapt, and Costco (NASDAQ: COST) and Constellation Brands (NYSE: STZ) are good examples.
Both companies
7 Out of 10 People Would Rather Be Home Than at a Multiplex
Multiplex operators see better days ahead. AMC Entertainment Holdings (NYSE: AMC) dreams about a future in which it can fire up its projectors again, and patrons will come rushing back to the
Is Blue Apron Stock a Buy?
In many regards, the company was built for the strange situation the world is now in. People don't want to leave their homes, but they still need to eat. Meal kit service Blue Apron (NYSE: APRN)
How the Coronavirus Pandemic Is Disrupting Appian's Business
Appian (NASDAQ: APPN) has been a volatile but profitable small-cap stock play in recent years. As of this writing, shares are up over 250% over the last three years. However, the low-code software
34% of Retirees Spend More Than They Budgeted, a Survey Says
When we're young, many of us envision retirement as a time of freedom and relaxation after decades in the workforce, but this isn't always how it goes. Retirement means life on a fixed income: an
NVIDIA Earnings: What to Watch Today After the Market Close
NVIDIA (NASDAQ: NVDA) is slated to report its first-quarter results for fiscal 2021 after the market close on Thursday, May 21.
The graphics processing unit (GPU) leader is going into its release on
Here's Why Warren Buffett's Berkshire Hathaway Has Lagged the S&P 500 (and Why It Could Have Been Worse)
The past three months have been brutal for the stock market. Even with the 35% gain the S&P 500 had made since its March 23 low, the broad large-cap index remains 13% below its Feb. 19 peak. And
Are These Two Unloved Tech Stocks Ready to Rebound?
SINA (NASDAQ: SINA) and Weibo (NASDAQ: WB) both reported first-quarter numbers on Tuesday that beat analysts' expectations. Both Chinese tech stocks initially rallied, but subsequently gave up their
Wix.com Sees a Surge in New Users Amidst Shelter-in-Place Orders
Often overlooked because of its larger and higher-growth peer Shopify, e-commerce enabler Wix.com (NASDAQ: WIX) had a great first quarter of 2020. Even as the economy took a nosedive into recession
These 2 Pot Stocks Have the Most Cash to Weather the Downturn
The global economy is currently in a state of turmoil because of the COVID-19 pandemic. For investors who are still looking to put their money in stocks during these challenging times, it is
HUYA Inc. (HUYA) Q1 2020 Earnings Call Transcript
Image source: The Motley Fool.
HUYA Inc. (NYSE: HUYA)Q1 2020 Earnings CallMay 21, 2020, 8:00 p.m. ET
Operator
Source Fool.com
3 Stocks to Buy if You're Worried About a Recession
Recessions create a tough environment to trade stocks in. Very few stocks do well when the economy is spluttering, so the best option for an investor generally is to find someplace to hide their
Analyst Says MGM Resorts Has No Catalysts for Growth in Immediate Future
Casinos may be opening up around the country, but MGM Resorts' (NYSE: MGM) stock is likely to be stuck in place, because there's nothing to move it higher.
Jefferies analyst David Katz downgraded
Is DocuSign Stock a Buy?
If you've had to sign a document recently, you probably didn't use a pen and paper. You likely encountered the leading e-signature platform from DocuSign (NASDAQ: DOCU) to capture your agreement
Aurora Cannabis Strikes a Deal to Enter the U.S. CBD Market
Aurora Cannabis (NYSE: ACB) is making a long-awaited move into the largest legal cannabis market in the world. The marijuana producer announced on Wednesday that it has entered into an agreement to
3 Big Takeaways From Royal Caribbean’s First-Quarter Earnings Call
On Wednesday, May 20, Royal Caribbean (NYSE: RCL) held its first-quarter 2020 conference call with analysts. No one really cared about the cruise company's 16.7% decline in revenue or the $1.48 in
UbiSoft Entertainment Inc. (UBSFY) Q4 2020 Earnings Call Transcript
Image source: The Motley Fool.
UbiSoft Entertainment Inc. (OTC: UBSFY)Q4 2020 Earnings CallMay 14, 2020, 12:15 p.m. ET
Yves Guillemot
Source Fool.com
Is Applied Materials Stock a Buy?
A lot has changed since Applied Materials (NASDAQ: AMAT) kicked off its 2020 fiscal year with a rebound in sales after a U.S.-China trade war and memory chip market slump the year prior. This time
Disney World's Top Rival Has a Reopening Plan
The economy has been reawakening in Central Florida after two months of shelter-in-place slumber, and it's time for the country's largest theme-park operators to step up with their reopening plans
Could You Use an Extra $2,779 Right Now? Here's How You May Be Able to Get It
With the COVID-19 crisis occupying so much of the news, it's easy to let a matter like taxes fall by the wayside, especially since the IRS pushed back the filing deadline for 2019 returns to July
4 Reasons Why Streaming Is Faring Better Than Cable During the COVID Pandemic
For most industries, the COVID-19 pandemic means that 2020 has been anything but business-as-usual. And, in most industries, that's a bad thing. But some companies and industries have been
Is DCP Midstream Stock a Buy?
DCP Midstream (NYSE: DCP) is a significant player in the North American midstream industry, but units of the MLP have been trading all over the place. At its worst, DCP was down more than 90% in
This Expense Is Costing 40% of Retirees More Than They Expected
We all hope we're going to remain healthy into our old age, but the truth is, you never can be sure. Even if you eat right and exercise regularly, you never know when an injury will send you to the
Will Good News Boost This Small-Cap Drug Company's Stock Even Higher?
Shares of CymaBay Therapeutics (NASDAQ: CBAY) have climbed nearly 143% since last week after it got great news about its orphan drug, seladelpar.
A phase 2B trial for the drug to see how it did


